EUVIMEDEUVIMED entdecken
Vergleichsstudie

Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism

Christine Van Laer, Marthe Vanrenterghem, Marc Jacquemin, Andreas Verstraete, Sarissa Baert, Cyrielle Kint, Mirjam Kruijt, L Renee Ruhaak, Veerle Labarque, Thomas Vanassche, Peter Verhamme, Kathelijne Peerlinck und 1 weitere

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.05.016 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Christine Van Laer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; Clinical Department of Labor…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Blood Coagulation, Thrombophilia, Anticoagulants. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Swedish Orphan Biovitrum, Novo Nordisk AS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Plasma-based assays or multigene panel testing can be used for the diagnosis of inherited venous thromboembolism (VTE). Our recent multigene panel data showed strictly concordant results between genetic and phenotypic laboratory testing in only half of the patients. OBJECTIVES: We aimed to evaluate in detail the correlation between genotype and laboratory phenotype for defects in natural anticoagulants. METHODS: Gene panel test results were compared with standard thrombophilia laboratory assay data, including protein C, protein S, and antithrombin plasma activity or antigen levels. We performed additional functional protein C and protein S clot-based assays and mass spectrometry for the detection of antithrombin molecular proteoforms. RESULTS: We detected PROC, PROS1, or SERPINC1 variants in 110 of 317 patients with VTE of which 61% were (likely)pathogenic variants. Oligogenic inheritance was present in 33% of all patients. Correlation studies showed that not all variants were associated with reduced plasma activity levels, while 14%, 20%, and 5% of our patients with VTE but without a genetic variant had reduced levels for protein C, protein S, and antithrombin, respectively. Additional clot-based assays could diagnose additional patients but not all. Mass spectrometry-based antithrombin assay was able to detect SERPINC1 missense variants in plasmas that were associated with normal antithrombin activity levels. CONCLUSIONS: Thrombophilia screening using plasma-based assays can lead to potential diagnostic misclassification. In contrast, multigene panel testing is more sensitive but still associated with the detection of variants of uncertain significance. Additional studies are required to clarify the role of panel testing for inherited VTE and the impact of oligogenic inheritance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismBlood CoagulationThrombophiliaAnticoagulantsHumansPhenotypeMaleProtein SFemaleProtein CAntithrombin IIIMiddle AgedAdultGenotypeGenetic Predisposition to DiseaseAgedBlood Coagulation TestsPredictive Value of TestsAntithrombinsMass SpectrometryYoung AdultGenetic Testing

Stichwörter der Autor:innen

antithrombinmultigene panel testingprotein Cprotein Sthrombophilia

Substanzen

Protein SSERPINC1 protein, humanProtein CAntithrombin IIIPROS1 protein, humanAnticoagulantsAntithrombins

Autor:innen und Institutionen

  • Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.
  • Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
  • Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
  • Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; Department of Pediatric Hemato-Oncology, University Hospitals Leuven, Leuven, Belgium.

Förderung

  • Swedish Orphan Biovitrum
  • Novo Nordisk AS

Zitieren

APA

Van Laer, C., Vanrenterghem, M., Jacquemin, M., Verstraete, A., Baert, S., Kint, C., Kruijt, M., Ruhaak, L. R., Labarque, V., Vanassche, T., Verhamme, P., Peerlinck, K., & Freson, K. (2025). Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.05.016

Vancouver

Van Laer C, Vanrenterghem M, Jacquemin M, Verstraete A, Baert S, Kint C, et al. Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.05.016

BibTeX
@article{VanLaer2025,
  author = {Van Laer, Christine and Vanrenterghem, Marthe and Jacquemin, Marc and Verstraete, Andreas and Baert, Sarissa and Kint, Cyrielle and Kruijt, Mirjam and Ruhaak, L Renee and Labarque, Veerle and Vanassche, Thomas and Verhamme, Peter and Peerlinck, Kathelijne and Freson, Kathleen},
  title = {Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.05.016}
}
Kostenlos starten →